Quoin Pharmaceuticals (QNRX) News Today $8.38 -0.09 (-1.06%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$8.31 -0.07 (-0.82%) As of 06/13/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 13, 2025 | globenewswire.comQNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseMarch 5, 2025 | msn.comQuoin files U.S., International patent applications for rapamycin formulationsMarch 4, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsMarch 4, 2025 | globenewswire.comQuoin Pharmaceuticals’ QRX003 shows potential efficacy in Netherton SyndromeFebruary 28, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFebruary 27, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFebruary 27, 2025 | globenewswire.comQuoin Pharmaceuticals launches first episode of ‘NETHERTON NOW’ seriesFebruary 25, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton SyndromeFebruary 25, 2025 | globenewswire.comQuoin Pharmaceuticals launches ‘NETHERTON NOW’ campaignFebruary 5, 2025 | markets.businessinsider.comQuoin Pharmaceuticals launches Netherton awareness campaignFebruary 4, 2025 | msn.comQuoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or CureFebruary 4, 2025 | globenewswire.comInsider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% SlideFebruary 2, 2025 | uk.finance.yahoo.comQuoin Pharmaceuticals: Buy Rating Affirmed Amidst Potential First-Mover Advantage in Netherton Syndrome TreatmentJanuary 25, 2025 | markets.businessinsider.comQuoin Pharmaceuticals reports setback in Netherton Syndrome studyJanuary 24, 2025 | msn.comQNRX Stock Hits 52-Week Low at $0.42 Amid Market ChallengesJanuary 24, 2025 | msn.comQuoin Pharmaceuticals announces further clinical evidence on QRX003 efficacyJanuary 24, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton SyndromeJanuary 23, 2025 | globenewswire.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome StudyJanuary 14, 2025 | finanznachrichten.deQuoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome StudyJanuary 14, 2025 | markets.businessinsider.comBuy Rating Reaffirmed for Quoin Pharmaceuticals Amid Promising QRX003 Developments and Market PotentialJanuary 8, 2025 | markets.businessinsider.comPRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome TrialsJanuary 7, 2025 | globenewswire.comQuoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical StudyJanuary 6, 2025 | globenewswire.comAnthony James Culverwell Acquires 100,000 Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) StockDecember 28, 2024 | insidertrades.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical StudyDecember 20, 2024 | finanznachrichten.deQuoin Pharmaceuticals announces FDA clearance to initiate QRX003 studyDecember 20, 2024 | markets.businessinsider.comQuoin Pharmaceuticals Announces Pricing of $6.8 Million Public OfferingDecember 20, 2024 | globenewswire.comQuoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical StudyDecember 19, 2024 | globenewswire.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical StudiesDecember 18, 2024 | finanznachrichten.deQuoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical StudiesDecember 18, 2024 | globenewswire.comQuoin Pharmaceuticals files to sell 19.23M ordinary sharesDecember 12, 2024 | markets.businessinsider.comQuoin Pharmaceuticals Annual Meeting Approves Key AmendmentsDecember 12, 2024 | markets.businessinsider.com Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address QNRX Media Mentions By Week QNRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNRX News Sentiment▼1.430.87▲Average Medical News Sentiment QNRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNRX Articles This Week▼21▲QNRX Articles Average Week Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALUR News Today NRXS News Today RVP News Today PETV News Today IRIX News Today NXGL News Today XAIR News Today VVOS News Today LFWD News Today MHUA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNRX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s worst nightmareThe President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QNRX Stock Free QNRX Stock Alerts